Novavax said its vaccine demonstrated 100% protection against moderate and severe disease, 90.4% overall efficacy, and met the primary endpoint of its pivotal phase 3 PREVENT-19 trial.
United States: Biotech company Novavax said on Monday that its Covid-19 vaccine is highly effective against COVID-19 in a large study and also protects against variants.
In an official announcement, the vaccine manufacturer announced that NVX-CoV2373, its COVID-19 vaccine based on recombinant protein nanoparticles, has demonstrated 100% protection against moderate and severe disease, an overall efficacy of 90, 4% and met the primary endpoint in its PREVENT -19 pivotal phase 3 trial.
Stanley C. Erck, President and CEO of Novavax, said in an official statement: “Today, Novavax takes one more step towards meeting the critical and persistent global public health need for additional COVID vaccines. -19. These clinical results support the fact that NVX- CoV2373 is extremely effective and provides complete protection against moderate and severe COVID-19 infections. “
“Novavax continues to work with a sense of urgency to complete our regulatory submissions and deliver this vaccine, built on a well-understood and proven platform, to a world that is still in dire need of vaccines,” added Stanley Erck.
Developed by the Maryland-based biotechnology company Novavax, the vaccine candidate called NVX-CoV2373 is a protein-based vaccine designed from the genetic sequence of the first strain of SARS-CoV-2, the virus that causes the disease. COVID-19.
NVX-CoV2373 contains purified protein antigen and cannot replicate or cause COVID-19. It is currently being evaluated in two pivotal phase 3 trials.
Approximately 30,000 volunteers over the age of 18 were recruited into vaccine trials in the United States and Mexico to assess efficacy, safety and immunogenicity, with an emphasis on recruiting a representative population of communities and demographic groups most affected by the disease.
In September 2020, Novavax announced an agreement with the Serum Institute of India to manufacture and deliver a vaccine against the coronavirus. With this agreement, Novavax increases its manufacturing capacity of NVX-CoV2373 to more than two billion doses per year, when all the planned capacity will have been commissioned by mid-2021.
